The proportion of patients who achieved biochemical control of acromegaly (defined as GH <2.5 μg/L and normal IGF-I) was similar for patients who did and did not experience hyperglycemia on pasireotide: 31.6% vs 30.2% (C2305), 15.8% vs 14.8% (C2402, pasireotide 40 mg) and 18.2% vs 23.8% (C2402, pasireotide 60 mg) achieved biochemical control. The gene discussed is IGF1; the disease is Hyperglycemia.